Last reviewed · How we verify
eN-Lac®
eN-Lac is a recombinant human lactoferrin used to treat various infections.
eN-Lac is a recombinant human lactoferrin used to treat various infections. Used for Treatment of neonatal sepsis.
At a glance
| Generic name | eN-Lac® |
|---|---|
| Also known as | eN-Lac® Capsules (Lactobacillus paracasei GMNL-32) |
| Sponsor | GenMont Biotech Incorporation |
| Drug class | Iron-binding protein |
| Target | Lactoferrin |
| Modality | Biologic |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
It works by binding to iron and inhibiting the growth of bacteria and other microorganisms. This helps to reduce the severity of infections and promote healing. Additionally, eN-Lac has anti-inflammatory properties that aid in the recovery process.
Approved indications
- Treatment of neonatal sepsis
Common side effects
- Hypersensitivity reactions
Key clinical trials
- the Efficacy and Safety of Probiotics eN-Lac® Capsules of Children With Perennial Allergic Rhinitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- eN-Lac® CI brief — competitive landscape report
- eN-Lac® updates RSS · CI watch RSS
- GenMont Biotech Incorporation portfolio CI